BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 7512277)

  • 1. The role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in chemotherapy for lung cancer.
    Saijo N; Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):54-8. PubMed ID: 7512277
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose intensity in small cell lung cancer.
    Thatcher N; Lee SM; Woll PJ; Middleton M; Anderson H; Burt P; Stout R
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):12-8; discussion 45-8. PubMed ID: 9578057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
    Rosell R; Gómez-Codina J; Anton A; Sánchez JJ; Vadell C
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):48-53. PubMed ID: 8153657
    [No Abstract]   [Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor in the treatment of small cell lung cancer.
    Wolf M; Klausmann M; Havemann K
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):51-6. PubMed ID: 7801147
    [No Abstract]   [Full Text] [Related]  

  • 5. Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?
    Croockewit AJ; Koopmans PP; de Pauw BE
    Clin Pharmacol Ther; 1996 Jan; 59(1):1-6. PubMed ID: 8549028
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Rüther U; Metzner B; Illiger HJ; Clemm C; Siegert W; Link H; Ostermann H; Schmoll HJ
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):57-63. PubMed ID: 7801148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving methotrexate/vinblastine/doxorubicin/cisplatin therapy for the treatment of transitional cell carcinoma of the urinary tract.
    Akaza H; Kotake T; Miyanaga N; Koiso K
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):70-4. PubMed ID: 7512280
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
    Shi YK; Sun Y; Su M
    Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):356-9. PubMed ID: 7895587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy dose-escalation with hemopoietic growth factor support in ovarian cancer.
    Willemse PH; Boonstra H; de Vries EG
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):44-50. PubMed ID: 7528450
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients].
    Shi YK; Zhou JC; Feng FY
    Zhonghua Zhong Liu Za Zhi; 1994 May; 16(3):207-10. PubMed ID: 7525173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
    de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
    [No Abstract]   [Full Text] [Related]  

  • 15. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy.
    Fisher DC; Peters WP
    Curr Opin Hematol; 1994 May; 1(3):221-7. PubMed ID: 9371286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study.
    Yanagawa H; Bando H; Takishita Y
    Anticancer Res; 1995; 15(2):613-6. PubMed ID: 7539241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomas.
    Gerhartz HH; Engelhard M; Brittinger G; Schlimok G; Thiel E; Huber C; Emmerich B; Schadek C; Brandmaier R; Stern AC
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):25-8. PubMed ID: 7528447
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of hematopoietic growth factors in the treatment of neoplastic diseases.
    St Onge J; Jacobson RJ
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):53-63. PubMed ID: 1380737
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.